2024 KIAS: Tumor Heterogeneity and Drug Resistance Session 2, Part2 

Session Two: Integrating Genomics & Signaling in Tumor Drug Response, featuring:
Neal Rosen
Memorial Sloan Kettering Cancer Center
"Mechanisms of primary resistance to RAS inhibitors"
Michael Yaffe
Koch Institute at MIT
"CRISPR-based interrogation of therapeutic resistance in ovarian cancer identifies known and novel targets"
Katherine Chiappinelli
George Washington University
"Targeting transposable elements to reverse cancer immune evasion"
ki.mit.edu/eve...